deaths (OS)progression or deaths (PFS)RFS/DFS

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

versus nivolumab alone
relatlimab plus nivolumab vs. nivolumab alone 1 - certainty unassessable-23%-